ISRCTN56416473 https://doi.org/10.1186/ISRCTN56416473

A multicentre randomised trial of short neo-adjuvant chemotherapy (VAPEC-B) plus involved field radiotherapy (MIT) versus mantle radiotherapy

Submission date 01/07/2001	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 01/07/2001	**Overall study status** Completed	
Last Edited 17/02/2015	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
- - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT00002987

Secondary identifying numbers
LY07

Study information

Scientific Title
A multicentre randomised trial of short neo-adjuvant chemotherapy (VAPEC-B) plus involved field radiotherapy (MIT) versus mantle radiotherapy

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Lung (non-small cell) cancer

Interventions
1. VAPEC-B regimen: minimal initial chemotherapy therapy involving vincristine, adriamycin, etoposide, cyclophosphamide and bleomycin, followed by involved field radiotherapy
2. Control regimen: mantle radiotherapy

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Vincristine, adriamycin, etoposide, cyclophosphamide and bleomycin

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/1995

Completion date
26/06/2001

Eligibility

Key inclusion criteria
1. Patients aged between 16 and 75 years
2. Histologically proven Hodgkin's disease, stage IA or IIA with no mediastinal bulk
3. No previous treatment
4. No previous malignancy other than basal cell carcinoma or cervical intra-epithelial neoplasms
5. No concurrent illness which would contraindicate chemotherapy or radiotherapy
6. Not documented evidence of Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
Not provided at time of registration

Key exclusion criteria
If Hodgkin's disease is below the diaphragm only, patients are not eligible for this trial

Date of first enrolment
01/01/1995

Date of final enrolment
26/06/2001

Locations

Countries of recruitment
United Kingdom

Study participating centre
-

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

Sponsor details
PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type
Charity

Website
http://www.cancer.org.uk

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results	abstract A-E08, 39	07/09/2004		No	No